A Phase 1, Double-blind, Placebo-controlled, Randomized, Parallel Group Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-04856883 In Adult Female Subjects With Type 2 Diabetes Mellitus
Phase of Trial: Phase I
Latest Information Update: 12 Feb 2018
At a glance
- Drugs PF 4856883 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Pfizer
- 10 Jun 2017 Biomarkers information updated
- 15 May 2012 Actual end date (Apr 2012) added as reported by ClinicalTrials.gov.
- 15 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.